We are investigating the safety and early effectiveness of a new treatment, MT-302, combined with CapOx chemotherapy for patients with metastatic esophagogastric cancer.
Health conditions and diseases that the clinical trial is designed to study and treat.
Metastatic esophagogastric cancer is a type of cancer that originates in the esophagus or stomach and has spread to other parts of the body, often leading to symptoms such as difficulty swallowing, weight loss, and abdominal pain.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.